IGC Pharma (IGC) announced the launch of Holiby, a wellness brand offering scientifically formulated products for immune defense and sustained ...

NEW YORK and VIENNA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ ... complete in the Phase 1b clinical trial evaluating HB-500 for the treatment of HIV, with 30 participants ...

Founded in 1935 by Khwaja Abdul Ahmeid, Cipla operates through two segments: Pharmaceuticals and New Ventures. Cipla Limited specialises in developing medications, primarily treating respiratory ...

US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...

Investing.com -- Alliance Pharma (LON:ALAPH) on Friday reported a disappointing trading update, prompting analysts at RBC Capital Markets to downgrade the stock to "sector perform.” The downgrade ...

HOOKIPA Pharma (HOOK) announced that enrollment is complete in the Phase 1b clinical trial evaluating HB-500 for the treatment of HIV, with 30 participants enrolled across five sites in the United ...

Investing.com -- Alliance Pharma (LON:ALAPH) on Friday reported a disappointing trading update, prompting analysts at RBC Capital Markets to downgrade the stock to "sector perform.” ...

Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil E-mail: [email protected] ...

NEW YORK and VIENNA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK ... today announced that enrollment is complete in the Phase 1b clinical trial evaluating HB-500 for the ...

HB-500 is a next-generation therapeutic vaccine being developed ... 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a clinical-stage biopharmaceutical company ...

The Phase 1b clinical trial (NCT06430905) is evaluating the safety and tolerability, reactogenicity, and immunogenicity to repeated doses of HB-500 in participants with HIV on suppressive ...